Travere Therapeutics (TVTX) Insider Trading & Ownership $17.18 -0.22 (-1.26%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Travere Therapeutics (NASDAQ:TVTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.75%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$2.16 M Get TVTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Travere Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TVTX Insider Buying and Selling by Quarter Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Travere Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/25/2024Sandra CalvinCAOSell12,090$18.30$221,247.00 10/4/2024Gary A LyonsDirectorSell40,000$14.73$589,200.00 9/30/2024Jeffrey A MecklerDirectorSell40,000$14.06$562,400.00 9/9/2024Christopher R ClineCFOSell2,490$11.52$28,684.80 9/9/2024Eric M DubeCEOSell21,125$11.52$243,360.00 9/9/2024Jula InrigInsiderSell2,191$11.52$25,240.32 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/9/2024William E RoteSVPSell4,387$11.52$50,538.24 9/4/2024Christopher R ClineCFOSell514$9.51$4,888.14 4/11/2024Christopher R ClineCFOSell54$6.74$363.96 2/1/2024Christopher R ClineCFOSell3,818$8.53$32,567.54 2/1/2024Eric M DubeCEOSell19,122$8.70$166,361.40 2/1/2024Peter HeermaInsiderSell4,195$8.53$35,783.35 2/1/2024Sandra CalvinCAOSell2,820$8.53$24,054.60 2/1/2024William E RoteSVPSell4,764$8.71$41,494.44 1/23/2024Christopher R ClineCFOSell853$9.07$7,736.71 1/23/2024Elizabeth E ReedSVPSell2,062$8.96$18,475.52 1/23/2024Eric M DubeCEOSell7,873$8.96$70,542.08 1/23/2024Peter HeermaInsiderSell1,559$9.07$14,140.13 1/23/2024Sandra CalvinCAOSell910$9.07$8,253.70 1/3/2024Jula InrigInsiderSell2,069$9.48$19,614.12 (Data available from 1/1/2013 forward) TVTX Insider Trading Activity - Frequently Asked Questions Who is on Travere Therapeutics's Insider Roster? The list of insiders at Travere Therapeutics includes Christopher R Cline, Elizabeth E Reed, Eric M Dube, Gary A Lyons, Jeffrey A Meckler, Jula Inrig, Laura Clague, Peter Heerma, Sandra Calvin, Steve Aselage, and William E Rote. Learn more on insiders at TVTX. What percentage of Travere Therapeutics stock is owned by insiders? 3.75% of Travere Therapeutics stock is owned by insiders. Learn more on TVTX's insider holdings. Which Travere Therapeutics insiders have been selling company stock? The following insiders have sold TVTX shares in the last 24 months: Christopher R Cline ($142,719.90), Elizabeth E Reed ($89,789.77), Eric M Dube ($983,379.28), Gary A Lyons ($589,200.00), Jeffrey A Meckler ($562,400.00), Jula Inrig ($87,412.69), Peter Heerma ($148,062.48), Sandra Calvin ($316,952.29), and William E Rote ($163,064.33). How much insider selling is happening at Travere Therapeutics? Insiders have sold a total of 219,788 Travere Therapeutics shares in the last 24 months for a total of $3,082,980.74 sold. Travere Therapeutics Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Compensation: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Compensation: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Compensation: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Compensation: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Compensation: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer 1 recent tradesMs. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business Officer More Insider Trading Tools from MarketBeat Related Companies TG Therapeutics Insider Trading Viking Therapeutics Insider Trading BridgeBio Pharma Insider Trading Crinetics Pharmaceuticals Insider Trading Krystal Biotech Insider Trading Arcellx Insider Trading ADMA Biologics Insider Trading Ultragenyx Pharmaceutical Insider Trading Apellis Pharmaceuticals Insider Trading Biohaven Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:TVTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
